天坛生物(600161.SH)发布上半年业绩，归母净利润6.33亿元，同比下降12.88%

Core Viewpoint - TianTan Biological (600161.SH) reported a revenue of 3.11 billion yuan for the first half of 2025, reflecting a year-on-year growth of 9.47%. However, the net profit attributable to shareholders decreased by 12.88% to 633 million yuan [1]. Financial Performance - The company achieved an operating income of 3.11 billion yuan, which is a 9.47% increase compared to the previous year [1]. - The net profit attributable to shareholders was 633 million yuan, showing a decline of 12.88% year-on-year [1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 618 million yuan, down 14.54% year-on-year [1]. - The basic earnings per share stood at 0.32 yuan [1].